RESUMO
BACKGROUND: Art v 1, Amb a 4, and Par h 1 are allergenic defensin-polyproline-linked proteins present in mugwort, ragweed, and feverfew pollen, respectively. We aimed to investigate the physicochemical and immunological features underlying the different allergenic capacities of those allergens. METHODS: Recombinant defensin-polyproline-linked proteins were expressed in E. coli and physicochemically characterized in detail regarding identity, secondary structure, and aggregation status. Allergenic activity was assessed by mediator releases assay, serum IgE reactivity, and IgE inhibition ELISA using sera of patients from Austria, Canada, and Korea. Endolysosomal protein degradation and T-cell cross-reactivity were studied in vitro. RESULTS: Despite variations in the proline-rich region, similar secondary structure elements were observed in the defensin-like domains. Seventy-four percent and 52% of the Austrian and Canadian patients reacted to all three allergens, while Korean patients were almost exclusively sensitized to Art v 1. This was reflected by IgE inhibition assays demonstrating high cross-reactivity for Austrian, medium for Canadian, and low for Korean sera. In a subgroup of patients, IgE reactivity toward structurally altered Amb a 4 and Par h 1 was not changed suggesting involvement of linear epitopes. Immunologically relevant endolysosomal stability of the defensin-like domain was limited to Art v 1 and no T-cell cross-reactivity with Art v 125-36 was observed. CONCLUSIONS: Despite structural similarity, different IgE-binding profiles and proteolytic processing impacted the allergenic capacity of defensin-polyproline-linked molecules. Based on the fact that Amb a 4 demonstrated distinct IgE-binding epitopes, we suggest inclusion in molecule-based allergy diagnosis.
Assuntos
Defensinas/imunologia , Epitopos/imunologia , Hipersensibilidade/imunologia , Prolina/imunologia , Alérgenos/sangue , Alérgenos/imunologia , Ambrosia/imunologia , Artemisia/imunologia , Áustria , Canadá , Defensinas/sangue , Ensaio de Imunoadsorção Enzimática , Epitopos/sangue , Humanos , Hipersensibilidade/sangue , Proteínas de Plantas/imunologia , Pólen/imunologia , Prolina/sangue , República da CoreiaRESUMO
Atopic dermatitis (AD) is a chronically relapsing inflammatory skin disease, associated with basophil infiltration into skin lesions and Staphylococcus aureus (S. aureus)-induced inflammation. Pattern recognition receptors (PRRs), including microbicidal peptide human neutrophil α-defensins (HNP) and dermcidin, can exert immunomodulating activity in innate immunity and skin inflammation. We investigated the plasma concentration of HNP and dermcidin, the expression of bacterial toll-like receptor (TLR) and nucleotide-binding oligomerization domain (NOD)-like receptors of basophils and plasma concentration and ex vivo induction of AD-related inflammatory cytokines and chemokines using ELISA and flow cytometry, in AD patients and control subjects. Plasma concentrations of HNP, dermcidin and AD-related Th2 chemokines CCL17, CCL22 and CCL27 were significantly elevated in AD patients compared with controls (all p < 0.05). Plasma concentrations of CCL27 and CCL22 were found to correlate positively with SCORing atopic dermatitis (SCORAD), objective SCORAD, % area affected, lichenification and disease intensity, and CCL27 also correlated positively with pruritus in AD patients (all p < 0.05). Protein expressions of NOD2 but not TLR2 of basophils were significantly down-regulated in AD patients compared with controls (p = 0.001). Correspondingly, there were lower ex vivo % inductions of allergic inflammatory tumor necrosis factor-α, IL-6 and CXCL8 from peripheral blood mononuclear cells upon NOD2 ligand S. aureus derived muramyl dipeptide stimulation in AD patients comparing with controls. The aberrant activation of bacterial PRRs of basophils and anti-bacterial innate immune response should be related with the allergic inflammation of AD.
Assuntos
Dermatite Atópica/sangue , Imunidade Inata , Inflamação/sangue , Proteína Adaptadora de Sinalização NOD2/sangue , Receptor 2 Toll-Like/sangue , Adolescente , Basófilos/imunologia , Basófilos/metabolismo , Basófilos/patologia , Quimiocina CCL22/sangue , Quimiocina CCL27/sangue , Criança , Defensinas/sangue , Defensinas/imunologia , Dermatite Atópica/imunologia , Dermatite Atópica/microbiologia , Dermatite Atópica/patologia , Feminino , Humanos , Inflamação/imunologia , Inflamação/microbiologia , Inflamação/patologia , Masculino , Peptídeos/sangue , Peptídeos/imunologia , Pele/imunologia , Pele/metabolismo , Pele/microbiologia , Pele/patologia , Staphylococcus aureus/efeitos dos fármacos , Staphylococcus aureus/patogenicidadeRESUMO
BACKGROUND: As defensins are dysregulated in psoriasis, the present work is aimed at the assessment of the impact of topical betamethasone with and without calcipotriol on human beta-defensin 2 (hBD-2) expression and serum level in a cohort Egyptian psoriatic patients. METHODS: A biopsy was performed at the site of psoriatic plaque for all patients participating in the study before application of any treatment. The first group of patients (n = 25) used an ointment containing a combination of calcipotriol and betamethasone dipropionate for 4 weeks while the second group (n = 25) used an ointment containing betamethasone valerate for the same period. For all patients, human beta defensin-2 expression and serum level was assayed before and after either treatment course. RESULTS: No statistically significant difference way detected between both groups as regards PASI score, hBD-2 expression or serum level before application of either treatment regimen, while those who used the combined regimen showed lower expression and serum level of hBD-2 associated with lower PASI score on comparison with those who followed the mono-therapy. CONCLUSIONS: Psoriasis treatment using the combined calcipotriol and betamethasone therapy is superior in effect to monotherapy using betamethasone alone. In addition, serum hBD-2 might be a useful marker for disease activity in psoriasis that can help assess the patient's clinical condition.
Assuntos
Betametasona/uso terapêutico , Calcitriol/análogos & derivados , Defensinas/metabolismo , Psoríase/sangue , Adulto , Betametasona/administração & dosagem , Calcitriol/administração & dosagem , Calcitriol/uso terapêutico , Defensinas/sangue , Humanos , Pessoa de Meia-IdadeRESUMO
OBJECTIVES: To analyse if defensins, immunomodulatory peptides involved in angiogenesis and elevated in the sera of systemic lupus erythematosus (SLE) patients, relate to cardiovascular disease in SLE. METHODS: Serum levels of the defensins human beta defensin 2 (hBD2) and human neutrophil peptide (HNP) of 72 SLE patients were determined by ELISA at baseline. Cardiovascular risk factors and the occurrence of cardiovascular events (CVE: stroke, claudication, angina pectoris, myocardial infarction) were recorded over 6 years. Intima media thickness of the carotid arteries (CIMT) was measured by ultrasound in 42 patients at baseline and at 4 years. Normally distributed log-transformed defensin levels (log-hBD2 and log-HNP) were used for statistical analysis. RESULTS: SLE patients who experienced a CVE had significantly higher log-hBD2 values and a likelihood-ratio for CVE of 2.23 when levels increased above 3.3 log(ng/ml). Using binary logistic regression analysis, log-hBD2 significantly contributed to a model also incorporating the number of traditional cardiovascular risk factors (dyslipidemia, hypertension, positive family history, age, smoking) as explanatory variables for the incidence of cardiovascular events. Moreover, SLE patients with progressive CIMT showed increased log-hBD2 and log-HNP values. Both defensin-levels also showed some correlation to the plaque stadium at baseline (hBD2: r2 0.10; HNP r2 0.12). Neither log-hBD2 nor log-HNP were correlated to traditional cardiovascular risk factors. CONCLUSIONS: HNP and especially hBD2 may be indicators of progressive cardiovascular disease in SLE.
Assuntos
Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/imunologia , Defensinas/sangue , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/imunologia , Angina Pectoris/sangue , Angina Pectoris/epidemiologia , Angina Pectoris/imunologia , Biomarcadores/sangue , Doenças Cardiovasculares/epidemiologia , Progressão da Doença , Dislipidemias/sangue , Dislipidemias/epidemiologia , Dislipidemias/imunologia , Feminino , Humanos , Claudicação Intermitente/sangue , Claudicação Intermitente/epidemiologia , Claudicação Intermitente/imunologia , Lúpus Eritematoso Sistêmico/epidemiologia , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/sangue , Infarto do Miocárdio/epidemiologia , Infarto do Miocárdio/imunologia , Fatores de Risco , Acidente Vascular Cerebral/sangue , Acidente Vascular Cerebral/epidemiologia , Acidente Vascular Cerebral/imunologiaRESUMO
A new algorithm has been developed for bioinformatics search of putative serum markers of cancer, which includes: 1) identification of microRNAs that are most often and most significantly overexpressed in tumors; 2) selection of mRNA targets regulated by microRNAs; 3) identification of mRNA targets encoding secreted proteins; 4) comparative analysis of mRNA transcription levels in normal and tumor tissues. Application of the algorithm led to discovery of seven putative serum markers of colon cancer: ADAMTS14, ANGPT2, CCL7, DEFA5, MMP11, MMP14, and PLAU. Experiments demonstrated that production of two out of seven proteins (MMP14 and DEFA5) is significantly increased in colon tumors vs. normal samples.
Assuntos
Biomarcadores Tumorais/sangue , Biologia Computacional/métodos , MicroRNAs/genética , Neoplasias/sangue , Algoritmos , Biomarcadores Tumorais/genética , Bases de Dados Genéticas , Defensinas/sangue , Defensinas/genética , Perfilação da Expressão Gênica , Humanos , Metaloproteinase 14 da Matriz/sangue , Metaloproteinase 14 da Matriz/genética , Neoplasias/diagnósticoRESUMO
Cardiovascular disease (CVD) risks persist in patients despite treatment. CVD susceptibility also varies with sex and ethnicity and is not entirely explained by conventional CVD risk factors. The aim of the present study was to identify novel CVD candidate markers in circulating Peripheral blood mononuclear cells (PBMCs) and plasma from Arab obese subjects with and without CVD using proteomic approaches. Human adults with confirmed CVD (n = 208) and matched non-CVD controls (n = 152) living in Kuwait were examined in the present cross-sectional study. Anthropometric and classical biochemical parameters were determined. We employed a shotgun proteomic profiling approach on PBMCs isolated from a subset of the groups (n = 4, each), and differentially expressed proteins selected between the two groups were validated at the mRNA level using RT-PCR (n = 6, each). Plasma levels of selected proteins from the proteomics profiling: Proteinase-3 (PR3), Annexin-A3 (ANX3), Defensin (DEFA1), and Matrix Metalloproteinase-9 (MMP9), were measured in the entire cohort using human enzyme-linked immunosorbent assay kits and were subsequently correlated with various clinical parameters. Out of the 1407 we identified and quantified from the proteomics profiling, 47 proteins were dysregulated with at least twofold change between the two subject groups. Among the differentially expressed proteins, 11 were confirmed at the mRNA levels. CVD influenced the levels of the shortlisted proteins (MMP9, PR3, ANX3, and DEFA1) in the PBMCs and plasma differentially. Despite the decreased levels of both protein and mRNA in PBMCs, PR3 circulating levels increased significantly in patients with CVD and were influenced by neither diabetes nor statin treatment. No significant changes were; however, observed in the DEFA1, MMP9, and ANX3 levels in plasma. Multivariate logistic regression analysis revealed that only PR3 was independently associated with CVD. Our results suggest that the dysregulation of PR3 levels in plasma and PBMCs reflects underlying residual CVD risks even in the treated population. More prospective and larger studies are required to establish the role of PR3 in CVD progression.
Assuntos
Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/metabolismo , Mieloblastina/metabolismo , Adulto , Anexina A3/análise , Anexina A3/sangue , Anexina A3/metabolismo , Árabes , Estudos Transversais , Defensinas/análise , Defensinas/sangue , Defensinas/metabolismo , Feminino , Perfilação da Expressão Gênica , Humanos , Kuweit/epidemiologia , Leucócitos/metabolismo , Leucócitos Mononucleares/metabolismo , Masculino , Metaloproteinase 9 da Matriz/análise , Metaloproteinase 9 da Matriz/sangue , Metaloproteinase 9 da Matriz/metabolismo , Pessoa de Meia-Idade , Mieloblastina/análise , Mieloblastina/sangue , Plasma/metabolismo , Estudos Prospectivos , Proteômica , RNA Mensageiro/genéticaRESUMO
We have employed the proteomic approach in combination with mass spectrometry to study the immune response of honey bee workers at different developmental stages. Analysis of the hemolymph proteins of noninfected, mock-infected and immune-challenged individuals by polyacrylamide gel electrophoresis showed differences in the protein profiles. We present evidence that in vitro reared honey bee larvae respond with a prominent humoral reaction to aseptic and septic injury as documented by the transient synthesis of the three antimicrobial peptides (AMPs) hymenoptaecin, defensin1, and abaecin. In contrast, young adult worker bees react with a broader spectrum of immune reactions that include the activation of prophenoloxidase and humoral immune responses. At least seven proteins appeared consistently in the hemolymph of immune-challenged bees, three of which are identical to the AMPs induced also in larvae. The other four, i.e., phenoloxidase (PO), peptidoglycan recognition protein-S2, carboxylesterase (CE), and an Apis-specific protein not assigned to any function (HP30), are induced specifically in adult bees and, with the exception of PO, are not expressed after aseptic injury. Structural features of CE and HP30, such as classical leucine zipper motifs, together with their strong simultaneous induction upon challenge with bacteria suggest an important role of the two novel bee-specific immune proteins in response to microbial infections.
Assuntos
Peptídeos Catiônicos Antimicrobianos/sangue , Abelhas/imunologia , Hemolinfa/imunologia , Proteínas de Insetos/metabolismo , Animais , Formação de Anticorpos , Peptídeos Catiônicos Antimicrobianos/química , Peptídeos Catiônicos Antimicrobianos/fisiologia , Abelhas/crescimento & desenvolvimento , Abelhas/microbiologia , Defensinas/sangue , Defensinas/química , Defensinas/fisiologia , Hemolinfa/metabolismo , Proteínas de Insetos/química , Proteínas de Insetos/fisiologia , Larva/imunologia , Larva/metabolismo , Larva/microbiologia , ProteômicaRESUMO
BACKGROUND: Plasma levels of neutrophil elastase (NE) are elevated in several inflammatory diseases and thus this enzyme might be a critical inflammatory marker. However, the role of NE in the pathogenesis of pneumonia has not been determined. The association between the severity of pneumonia and blood levels of inflammatory markers could be relevant to developing a useful indicator of severity and new therapeutic strategies for pneumonia. METHODS: We searched for a useful predictive marker and a new therapeutic strategy against pneumonia, using a prospective, multicenter, population-based investigation. Several inflammatory markers in the circulation including NE, cytokines, defensins, C-reactive protein (CRP) and white blood cell (WBC) counts as well as clinical features were prospectively monitored in 28 adult patients with moderate (n=11) and severe pneumonia (n=17) over a period of 14 days. RESULTS: The value of plasma NE was the highest at entry and significantly declined 2 days later. Trends of cytokines, defensins, CRP and WBC counts were similar but blunter. Microorganisms and the outcome of initial treatment did not significantly affect plasma NE levels. Baseline values of plasma NE were significantly higher in severe, than in moderate pneumonia and this difference between the two types of pneumonia persisted longer than those of any other markers. CONCLUSIONS: Neutrophil elastase appears to play a critical role in severe pneumonia and determination of its concentration in blood could be a useful indicator of severity. Furthermore, clinical trials of anti-NE drugs in patients with severe pneumonia should be promising.
Assuntos
Mediadores da Inflamação/sangue , Elastase de Leucócito/sangue , Pneumonia Bacteriana/sangue , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Citocinas/sangue , Defensinas/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pneumonia Bacteriana/enzimologia , Pneumonia Bacteriana/terapia , Estudos Prospectivos , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
Defensins are endogenous antibiotics and regulators of inflammation, immunity and wound repair. Their concentrations are substantially increased in bronchoalveolar lavage fluid (BALF) of patients with infectious lung diseases. alpha-defensin (HAD) levels are also elevated in patients with idiopathic pulmonary fibrosis (IPF) and correlated with the decline in pulmonary function tests, suggesting the association of defensins with the pathogenesis of interstitial lung diseases. The aim of this study was to determine the profile of defensins in interstitial lung diseases. Serum and BALF levels of HAD and beta-defensin 1 and 2 (HBD-1, and -2) were measured by radioimmunoassay in 63 patients with interstitial lung diseases, including idiopathic pulmonary alveolar proteinosis (PAP), IPF, nonspecific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP) and pulmonary sarcoidosis, and in 9 healthy volunteers as controls. Levels of HAD in BALF of patients with PAP were significantly higher than those in controls and patients with COP and sarcoidosis. Serum levels of HAD in all groups were significantly higher than those in controls. Levels of HBD-1 and -2 in BALF of patients with PAP were extremely high in all subjects. Serum levels of HBD-1 were higher in all patient groups, with the exception of those with PAP, and those of HBD-2 were also higher in patients with IPF and sarcoidosis, compared with controls. BALF of PAP patients, but not IPF patients and controls, expressed antimicrobial activity against Pseudomonas aeruginosa and Staphylococcus aureus. Our findings suggest different kinetics of HAD and HBD-1 and -2 in serum and BALF of interstitial lung diseases and that these antimicrobial peptides in the airway lumen may contribute to prevention of bacterial airway infections in PAP.
Assuntos
Anti-Infecciosos/análise , Líquido da Lavagem Broncoalveolar/química , Defensinas/análise , Proteinose Alveolar Pulmonar/metabolismo , Adulto , Idoso , Anti-Infecciosos/sangue , Líquido da Lavagem Broncoalveolar/citologia , Contagem de Células , Contagem de Colônia Microbiana , Defensinas/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Proteinose Alveolar Pulmonar/sangue , alfa-Defensinas/análise , alfa-Defensinas/sangue , beta-Defensinas/análise , beta-Defensinas/sangueRESUMO
Hepatitis C virus (HCV) is the major etiological agent of human non-A and non-B hepatitis, affecting around 180 million people worldwide. Defensins, small cysteine-rich cationic peptides, are shown to have potent antibacterial, antiviral, and antifungal properties. Defensins can be found in both normal and microbial infected patients, at variable concentrations. Notably, viral infections are often associated with elevated concentrations of defensins. The current study aimed to estimate the concentrations of total, α-, and ß-defensins in serum taken from normal and HCV-infected patients. 12 healthy (noninfected) and 34 HCV-infected patients were enrolled. Standardized immunoassay kits were used to obtain serum concentrations of defensins. The obtained results were calibrated against kit standard reagents. Total defensin concentrations in HCV-infected patients were significantly higher (2- to 105-fold) compared to healthy individuals. The concentrations of α-defensins were also significantly elevated in the HCV-infected patients (31-1398 ng/50 µL). However, concentrations of ß-defensins ranged from 44.5 ng/50 µL to 1056 ng/50 µL. The results did not reveal differences in serum defensin concentration between male and female HCV-infected patients. A-defensin concentration of ≥250 ng/50 µL was found to contain more ß-defensins than total defensins and α-defensins. This study concludes, for the first time, that serum defensin levels are elevated in HCV-infected patients.
Assuntos
Defensinas/sangue , Hepacivirus/imunologia , Hepatite C/sangue , Hepatite C/imunologia , Estudos de Casos e Controles , Ensaio de Imunoadsorção Enzimática , Feminino , Hepacivirus/genética , Hepatite C/virologia , Anticorpos Anti-Hepatite C/sangue , Anticorpos Anti-Hepatite C/imunologia , Humanos , Masculino , Carga Viral , alfa-Defensinas/sangue , beta-Defensinas/sangueRESUMO
STUDY OBJECTIVES: To investigate the roles of human alpha-defensin (HAD), human beta-defensin (HBD)-1, and HBD-2, novel antimicrobial peptides, in patients with Mycobacterium avium-intracellulare infection (MAI). PATIENTS: The study included 25 patients (10 men) with MAI who visited our hospital between June 1998 and August 1999. MEASUREMENTS AND RESULTS: In patients with pulmonary MAI, we measured HAD and HBD-1, and HBD-2 levels in plasma and in BAL fluid (BALF) by radioimmunoassay. Plasma concentrations of HAD and HBD-2 in those patients were higher than those in control subjects, whereas HBD-1 levels were similar to those in the control subjects. High levels of HAD and HBD-2, but not HBD-1, also were observed in the BALF of MAI patients. There was a positive correlation between HAD and interleukin (IL)-8 concentrations in the BALF of patients with MAI. BALF HBD-2 concentrations also correlated positively with those of plasma HBD-2 and BALF IL-1 beta in MAI patients. Patients with cavity formation on the chest roentgenogram had higher HAD and HBD-2 levels in their BALF than those of patients without cavity formation. Treatment with clarithromycin combined with two or three other antibiotics, including ethambutol, rifampicin, ofloxacin, or ciprofloxacin, for at least 6 months resulted in a significant fall in plasma HBD-2 concentrations in responders, but not in nonresponders. CONCLUSION: Our findings suggest that HAD and HBD-2 may participate in host defense and local remodeling of the respiratory tract in patients with MAI and that plasma HBD-2 levels may be a useful marker of disease activity in patients with pulmonary MAI.
Assuntos
Líquido da Lavagem Broncoalveolar/química , Defensinas/análise , Infecção por Mycobacterium avium-intracellulare/metabolismo , Antibacterianos , Líquido da Lavagem Broncoalveolar/citologia , Contagem de Células , Defensinas/sangue , Quimioterapia Combinada/uso terapêutico , Feminino , Humanos , Interleucina-1/análise , Interleucina-8/análise , Masculino , Pessoa de Meia-Idade , Infecção por Mycobacterium avium-intracellulare/tratamento farmacológico , RadioimunoensaioRESUMO
BACKGROUND: We hypothesized that systemic release of endogenous leukocyte-derived polypeptide antimicrobial defensins (polymorphonuclear leukocyte-specific) and lactoferrin (polymorphonuclear leukocyte and epithelial cell derived) occurs in nonneutropenic children with severe sepsis. METHODS: We performed a prospective cross-sectional and longitudinal study in a university children's hospital pediatric intensive care unit. Ninety-two consecutive children meeting criteria for sepsis and 14 critically ill children without sepsis (controls) were enrolled, and plasma defensins and lactoferrin concentrations were measured on Days 1 and 3 of sepsis. RESULTS: Nonneutropenic sepsis patients (n = 71) had increased defensins and lactoferrin plasma concentrations compared with critically ill control patients [defensins, 450 ng/ml vs. 150 ng/ml; lactoferrin, 332 ng/ml vs. 176 ng/ml (median values); P < 0.05] and neutropenic sepsis patients [n = 21; defensins, 450 ng/ml vs. 50 ng/ml; lactoferrin, 332 ng/ml vs. 20 ng/ml (median values); P < 0.05]. Neutropenic sepsis patients had similar plasma defensin concentrations and a decrease in plasma lactoferrin concentrations compared with control patients (P < 0.05). Defensins and lactoferrin plasma concentrations correlated to total white blood cell and absolute neutrophil count (P < 0.05). There was no association between plasma defensin concentration and organ failure or outcome; however, increased plasma lactoferrin concentrations were observed with the development of organ failure (P < 0.05). CONCLUSION: These data suggest that increased circulating defensins and lactoferrin release are dependent in part on neutrophil count and might play a role in host defense in children with severe sepsis.
Assuntos
Defensinas/sangue , Lactoferrina/sangue , Neutropenia/etiologia , Sepse/imunologia , Adolescente , Criança , Pré-Escolar , Estudos Transversais , Feminino , Humanos , Lactente , Recém-Nascido , Unidades de Terapia Intensiva Pediátrica , Masculino , Neutropenia/imunologia , Estudos Prospectivos , Sepse/patologia , Índice de Gravidade de DoençaRESUMO
Human neutrophil peptides (HNPs) 1, 2 and 3 are antimicrobial peptides localized in the azurophil granules of neutrophils. We investigated the effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on the biosynthesis of HNPs 1-3 using a sensitive radioimmunoassay and Northern blot analysis. Seven patients with lung cancer were first treated with various anticancer agents for 3 days (days 1-3) followed by treatment with rhG-CSF (2 microgram/kg weight/day) for 7 days (days 8-14). Chemotherapy caused neutropenia but the neutrophil count increased biphasically between days 8 and 14. Chemotherapy did not change the baseline plasma concentration of HNPs 1-3 (74.1+/-2.1 pmol/ml) but the concentration increased from day 12, 5 days after commencement of rhG-CSF therapy, to reach a peak value of 430.8+/-57.0 pmol/ml on day 15, 1 day after the last administration of rhG-CSF. Baseline HNPs 1-3 content per neutrophil was 0.59+/-0.02 fmol, decreased to 0.30+/-0.07 fmol on day 9, then increased to 0.78+/-0.07 fmol on day 15. Analyses of peripheral blood neutrophils by Northern blot and reverse-phase high-performance liquid chromatography showed that the amounts of HNPs 1-3 mRNA and precursors of HNPs 1-3 markedly increased in response to rhG-CSF. Our results indicate that recombinant hG-CSF does not only increase neutrophil count but stimulates HNPs 1-3 biosynthesis in neutrophils, thus enhancing the host defense system of compromised hosts with neutropenia.
Assuntos
Anti-Infecciosos/sangue , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Defensinas/sangue , Defensinas/genética , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Neoplasias Pulmonares/sangue , Neutropenia/tratamento farmacológico , Neutrófilos/fisiologia , alfa-Defensinas , Adenocarcinoma/sangue , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/patologia , Idoso , Carcinoma de Células Pequenas/sangue , Carcinoma de Células Pequenas/tratamento farmacológico , Carcinoma de Células Pequenas/patologia , Feminino , Fator Estimulador de Colônias de Granulócitos/farmacologia , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Neutropenia/sangue , Neutropenia/induzido quimicamente , Neutrófilos/efeitos dos fármacos , Proteínas RecombinantesRESUMO
We studied the peculiarities of functional activity of peripheral blood leukocytes in different etiological variants and clinical forms of tick-borne infections in 629 children aged from 1 to 14 years. The decrease of biocide potential of neutrophils was accompanied by most severe clinical manifestations. The analysis of changes in defensin levels in different clinical forms of tick-borne infections revealed the most significant changes in cases of mixed infection. The dynamics of functional activity of leukocytes during the cycloferon immunotherapy reflected the effectiveness of recovering process in biocide potential regardless of the infection etiology. The main advantage of immunotherapy is the possibility of its use in the complex treatment before the serologic confirmation of the diagnosis regardless of disease etiology.
Assuntos
Imunoterapia , Leucócitos/imunologia , Doenças Transmitidas por Carrapatos/terapia , Acridinas/uso terapêutico , Adolescente , Criança , Pré-Escolar , Defensinas/sangue , Defensinas/imunologia , Feminino , Humanos , Imunoglobulinas/uso terapêutico , Fatores Imunológicos/uso terapêutico , Lactente , Indutores de Interferon/uso terapêutico , Masculino , Neutrófilos/imunologia , Doenças Transmitidas por Carrapatos/imunologia , Doenças Transmitidas por Carrapatos/microbiologiaRESUMO
OBJECTIVE: Our purpose was to determine whether maternal plasma levels of neutrophil granule products are elevated in patients with chorioamnionitis after preterm premature rupture of membranes (PROM). STUDY DESIGN: Fifty-two patients between 24 and 34 weeks' gestation with preterm PROM were included. Plasma samples for defensins and lactoferrin were collected throughout latency. Fifty-two control subjects between 26 and 30 weeks' gestation were recruited for baseline levels. RESULTS: Mean control defensin levels were compared with mean defensin levels on admission (668 ng/mL vs 5665 ng/mL, P<.01). Mean defensin levels on admission in patients without chorioamnionitis were compared with those of patients in whom histologic chorioamnionitis developed (520 ng/mL vs 9163 ng/mL, P<.01). The same relationships were not demonstrated for lactoferrin. With use a defensin value of 1500 ng/mL on admission, the sensitivity is 76% and specificity is 94% in predicting histologic chorioamnionitis. CONCLUSIONS: Maternal plasma levels of defensins are markers of histologic chorioamnionitis in patients after preterm PROM.
Assuntos
Anti-Infecciosos/sangue , Corioamnionite/sangue , Defensinas/sangue , Ruptura Prematura de Membranas Fetais/sangue , Lactoferrina/sangue , Neutrófilos/metabolismo , Corioamnionite/complicações , Corioamnionite/diagnóstico , Grânulos Citoplasmáticos/metabolismo , Feminino , Ruptura Prematura de Membranas Fetais/complicações , Idade Gestacional , Humanos , Neutrófilos/ultraestrutura , Placenta/patologia , Gravidez , Sensibilidade e Especificidade , Fatores de TempoRESUMO
Rhesus theta-defensin 1 (RTD-1) is a unique tridisulfide, cyclic antimicrobial peptide formed by the ligation of two 9-residue sequences derived from heterodimeric splicing of similar 76-amino acid, alpha-defensin-related precursors, termed RTD1a and RTD1b (Tang, Y. Q., Yuan, J., Osapay, G., Osapay, K., Tran, D., Miller, C. J., Ouellette, A. J., and Selsted, M. E. (1999) Science 286, 498-502). The structures of RTD-2 and RTD-3 were predicted to exist if homodimeric splicing of the RTD1a and RTD1b occurs in vivo. Western blotting disclosed the presence of putative theta-defensins, distinct from RTD-1, in leukocyte extracts. Two new theta-defensins, RTD-2 and RTD-3, were purified by reverse-phase high performance liquid chromatography and characterized by amino acid analysis, matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy, and comparison to the synthetic standards. RTD-2 and RTD-3 are the predicted homodimeric splicing products of RTD1b and RTD1a, respectively. The cellular abundances of RTD-1, -2, and -3 were 29:1:2, indicating that there is a preference for the heterodimeric ligation that generates RTD-1. RTD-1, -2, and -3 had similar antimicrobial activities against Staphylococcus aureus, Candida albicans, and Cryptococcus neoformans, whereas the activity of RTD-2 against Escherichia coli was 2-3-fold less than those of RTD-1 and RTD-3. Equal amounts of each theta-defensin bound to E. coli cells, indicating that the differences in antibacterial activities are the result of post-binding processes.